Proving the Business Case for the Internet of Things

European wearables pilot to improve mental health

William Payne
May 4, 2016
An EU connected health project, involving hospitals, universities and vendors from all over the continent, has launched in London to investigate how wearable technologies and cloud based IoT data streaming analytics could improve the lives of people with major mental health disorders.
The Radar-CNS (remote assessment of disease and relapse – central nervous system) programme aims to improve patients’ quality of life, and potentially change how these and other chronic disorders are treated.
The pilot will investigate how continuous remote assessment using smartphones and wearable devices could provide a complete picture of a patient’s condition at a level of detail previously unachievable. Wearables combined with real-time analytics could also potentially allow treatment to begin before a patient’s health deteriorates, preventing the patient relapsing or becoming more ill before they seek treatment.
Radar-CNS is jointly led by King’s College London and Janssen Pharmaceutica, funded by the Innovative Medicines Initiative (a public-private partnership established between the European Federation of Pharmaceutical Industries & Associations and the European Union) and includes 24 partners from across Europe and the USA.
The programme brings together experts from diverse fields including clinical research, engineering, computer science, information technology, data analytics and health services.
Germany’s Software AG will provide elements of its digital business platform, including Apama big data streaming analytics and Terracotta in-memory data fabric.
Epilepsy, depression and multiple sclerosis are distinct disorders, with different causes and symptoms, all of which can be severely detrimental to patients’ quality of life and life expectancy. For all three disorders, patients often experience periods where their symptoms are manageable, followed by periods of deterioration and acute illness (relapse). Patient surveys have repeatedly highlighted the need to predict when relapses will happen and to improve the treatments that are available to stop them from occurring.
Co-lead of the Radar-CNS programme Matthew Hotopf, director of the NIHR Maudsley Biomedical Research Centre in London, said: “In recent years, the quality and quantity of data that we can collect using wearable devices and smartphones has exploded. It may be that this sort of data can improve clinical care simply by providing more accurate information. Better still, it may be possible to spot when a patient is getting into trouble before their clinic visit.
“For example, in depression, someone’s behaviour may change even before they have noticed they are struggling – their sleep may get worse, or they may stop doing so much in the weeks leading up to a relapse. Radar-CNS will exploit the huge potential of wearable technologies to improve the lives of the millions of people worldwide with chronic illnesses like epilepsy, depression and multiple sclerosis.”
Wherever possible, Radar-CNS will use inexpensive and widely available technology, so the end results can be made available to as many patients as possible. The research will also be developed in a way that allows the results to be transferred to other diseases, potentially allowing the benefits of remote measurement technologies to become pervasive in medicine, and transforming the way the world thinks about prevention and cure.
The pilot will depend on real-time streaming data analytics to provide immediate analysis of patients’ conditions. Software AG in-memory data management will be used to handle very large data sets in real time, and the company’s Apama big data streaming analytics will provide real-time patient condition analysis.
Giles Nelson, Software AG’s senior vice president of product management, said: “The digital business platform will enable researchers to access unprecedented amounts of data from wearable smart devices in real time for deep insights into brain disorders, personalised analytics and detect early warning signs of aberrant behaviour.”
Patients will be involved in Radar-CNS from the start, helping identify the most important symptoms to target. They will also advise researchers on how best to implement remote measurement technologies in a way that is acceptable and engaging to patients, including accounting for privacy and security.
“Our goal is to improve clinical care and outcomes by using data generated by patients as they go about their daily lives to predict and pre-empt relapses and improve their quality of life,” said co-lead of the Radar-CNS programme Vaibhav Narayan from Janssen Research & Development, an affiliate of Janssen Pharmaceutica. “Such predictive medicine will be backed by scientific evidence and will meet regulatory standards. At the same time, the privacy and security of patients and their care-givers will be fully protected.”
Radar-CNS runs from this year until 2021, and is jointly led by King’s College London and Janssen Pharmaceutica.